BACKGROUND: Gastric adenocarcinoma is a leading cause of cancer mortality. The role of dopamine and cAMP regulated phosphoprotein MW 32 kDa (DARPP-32) overexpression in the gastric tumorigenesis cascade remains unclear. METHODS: The expression of DARPP-32 in the multistep carcinogenesis cascade was examined using immunohistochemistry analysis on 533 samples. The contribution of DARPP-32 in cellular transformation and molecular signaling was investigated using NIH3T3, AGS, and SNU16 cells. RESULTS: The composite expression score (CES), calculated from immunostaining patterns, increased significantly from normal or gastritis to metaplasia, dysplasia, and adenocarcinoma (P < .001). In patients with normal stomach or gastritis and tumor samples, a 76% and 77% chance, respectively, was found (P < .001) that CES was higher in the tumor. High median CES correlated with well- or moderately differentiated (P = .03) gastric adenocarcinomas. NIH3T3 cells transfected with DARPP-32 demonstrated increased levels of phospho-AKT and a 5-fold increase in the number of foci as compared with the control (P = .02). DARPP-32 expression in AGS cells led to increased protein levels of phospho-AKT and BCL-2. For validation, the knockdown of endogenous DARPP-32 expression in SNU16 cells using shRNA resulted in decreased levels of phospho-AKT phosphorylation and BCL-2. CONCLUSION: Our results suggest that DARPP-32 overexpression may participate in the transition to intestinal metaplasia and in the progression to neoplasia. The ability of DARPP-32 to transform NIH3T3 cells and to regulate AKT and BCL-2 underscores its possible oncogenic potential. Copyright 2010 Mosby, Inc. All rights reserved.
BACKGROUND:Gastric adenocarcinoma is a leading cause of cancer mortality. The role of dopamine and cAMP regulated phosphoprotein MW 32 kDa (DARPP-32) overexpression in the gastric tumorigenesis cascade remains unclear. METHODS: The expression of DARPP-32 in the multistep carcinogenesis cascade was examined using immunohistochemistry analysis on 533 samples. The contribution of DARPP-32 in cellular transformation and molecular signaling was investigated using NIH3T3, AGS, and SNU16 cells. RESULTS: The composite expression score (CES), calculated from immunostaining patterns, increased significantly from normal or gastritis to metaplasia, dysplasia, and adenocarcinoma (P < .001). In patients with normal stomach or gastritis and tumor samples, a 76% and 77% chance, respectively, was found (P < .001) that CES was higher in the tumor. High median CES correlated with well- or moderately differentiated (P = .03) gastric adenocarcinomas. NIH3T3 cells transfected with DARPP-32 demonstrated increased levels of phospho-AKT and a 5-fold increase in the number of foci as compared with the control (P = .02). DARPP-32expression in AGS cells led to increased protein levels of phospho-AKT and BCL-2. For validation, the knockdown of endogenous DARPP-32expression in SNU16 cells using shRNA resulted in decreased levels of phospho-AKT phosphorylation and BCL-2. CONCLUSION: Our results suggest that DARPP-32 overexpression may participate in the transition to intestinal metaplasia and in the progression to neoplasia. The ability of DARPP-32 to transform NIH3T3 cells and to regulate AKT and BCL-2 underscores its possible oncogenic potential. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Asta Varis; Maija Wolf; Outi Monni; Marja-Leena Vakkari; Arto Kokkola; Chris Moskaluk; Henry Frierson; Steven M Powell; Sakari Knuutila; Anne Kallioniemi; Wa'el El-Rifai Journal: Cancer Res Date: 2002-05-01 Impact factor: 12.701
Authors: Wa'el El-Rifai; Michael F Smith; Guolian Li; Andy Beckler; Virginia S Carl; Elizabeth Montgomery; Sakari Knuutila; Christopher A Moskaluk; Henry F Frierson; Steven M Powell Journal: Cancer Res Date: 2002-07-15 Impact factor: 12.701
Authors: Alex Boussioutas; Hong Li; Jia Liu; Paul Waring; Stephen Lade; Andrew J Holloway; Douglas Taupin; Kylie Gorringe; Izhak Haviv; Paul V Desmond; David D L Bowtell Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai Journal: Mol Cancer Ther Date: 2012-02-01 Impact factor: 6.261
Authors: Mohammed Soutto; Abbes Belkhiri; M Blanca Piazuelo; Barbara G Schneider; Dunfa Peng; Aixiang Jiang; M Kay Washington; Yasin Kokoye; Sheila E Crowe; Alexander Zaika; Pelayo Correa; Richard M Peek; Wael El-Rifai Journal: J Clin Invest Date: 2011-04-01 Impact factor: 14.808
Authors: Shoumin Zhu; Mohammed Soutto; Zheng Chen; DunFa Peng; Judith Romero-Gallo; Uma S Krishna; Abbes Belkhiri; M Kay Washington; Richard Peek; Wael El-Rifai Journal: Gut Date: 2016-09-02 Impact factor: 23.059